Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesonide Respimat
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Budesonide Respimat is an inhaled corticosteroid (ICS) formulation developed by Boehringer Ingelheim for the treatment of asthma. It utilizes the proprietary Respimat Soft Mist Inhaler (SMI) technology, which delivers a slow-moving, long-lasting aerosol mist that enhances lung deposition and reduces oropharyngeal deposition compared to traditional pressurized metered-dose inhalers (pMDIs) or dry powder inhalers (DPIs). As a glucocorticoid receptor agonist, budesonide exerts potent anti-inflammatory effects within the airways, reducing the recruitment and activation of inflammatory cells such as mast cells, eosinophils, and lymphocytes. This formulation was evaluated in Phase 3 clinical trials to compare its efficacy and safety against the Turbohaler dry powder formulation in adult patients with moderate to severe asthma. Although the trials demonstrated therapeutic non-inferiority, Boehringer Ingelheim primarily focused on commercializing Respimat-based combination therapies rather than this specific budesonide monotherapy.
- Brand names
- Respimat Budesonide
- Other names
- budesonide (Respimat)BI budesonide Respimat
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on budesonide Respimat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesonide Respimat.